Cargando…

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy

Triple‐negative breast cancers (TNBCs) are highly aggressive, metastatic and recurrent. Cytotoxic chemotherapies with limited clinical benefits and severe side effects are the standard therapeutic strategies, but, to date, there is no efficacious targeted therapy. Literature and our data showed that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Si, Yingnan, Xu, Yuanxin, Guan, JiaShiung, Chen, Kai, Kim, Seulhee, Yang, Eddy S., Zhou, Lufang, Liu, Xiaoguang Margaret
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837297/ https://www.ncbi.nlm.nih.gov/pubmed/33531889 http://dx.doi.org/10.1002/elsc.202000027

Ejemplares similares

Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
por: Si, Yingnan, et al.
Publicado: (2021)

Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment
por: Si, Yingnan, et al.
Publicado: (2020)

Antibody–Drug Conjugate to Treat Meningiomas
por: Chen, Kai, et al.
Publicado: (2021)

Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers
por: Si, Yingnan, et al.
Publicado: (2022)

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
por: Si, Yingnan, et al.
Publicado: (2021)

Anti-SSTR2 Antibody-drug Conjugate for Neuroendocrine Tumor Therapy
por: Si, Yingnan, et al.
Publicado: (2020)

Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
por: Chen, Kai, et al.
Publicado: (2022)

A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)
por: Zhang, Jiashuai, et al.
Publicado: (2023)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Novel biomanufacturing platform for large-scale and high-quality human T cells production
por: Ou, Jianfa, et al.
Publicado: (2019)

Characterization of the far-red fluorescent probe MitoView 633 for dynamic mitochondrial membrane potential measurement
por: Ernst, Patrick, et al.
Publicado: (2023)

Bioprocess development of antibody-drug conjugate production for cancer treatment
por: Ou, Jianfa, et al.
Publicado: (2018)

EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment
por: Zhang, Chaoyu, et al.
Publicado: (2022)

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
por: Zoeller, Jason J., et al.
Publicado: (2020)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Near-infrared photothermal therapy using anti-EGFR-gold nanorod conjugates for triple negative breast cancer
por: Zhang, Meihua, et al.
Publicado: (2017)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Radosevic-Robin, Nina, et al.
Publicado: (2021)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer
por: Zhou, Dan-Dan, et al.
Publicado: (2021)

Anti-EGFR antibody conjugated silica nanoparticles as probes for lung cancer detection
por: Wan, Jun, et al.
Publicado: (2017)

Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody
por: Tsujii, Toshiyasu, et al.
Publicado: (2016)

Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen
por: Nagaya, Tadanobu, et al.
Publicado: (2015)

Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
por: Agnello, Lisa, et al.
Publicado: (2021)

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells
por: Nowsheen, Somaira, et al.
Publicado: (2012)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin
por: Gan, Hui K, et al.
Publicado: (2021)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates
por: Abdollahpour-Alitappeh, Meghdad, et al.
Publicado: (2017)

An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
por: Jin, Junyeong, et al.
Publicado: (2018)

Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
por: Montero, Juan Carlos, et al.
Publicado: (2022)

RAFT Polymer–Antibody Conjugation: Squaramide Ester Chemistry Leads to Conjugates with a Therapeutic Anti-EGFR Antibody with Full Retention of Activity and Increased Tumor Uptake In Vivo
por: Ardana, Aditya, et al.
Publicado: (2023)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
por: Jiang, Weihua, et al.
Publicado: (2020)

Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates
por: Tikum, Anjong Florence, et al.
Publicado: (2022)

Triple-negative and triple-positive breast cancer cells reciprocally control their growth and migration via the S100A4 pathway
por: Dukhanina, Elena A., et al.
Publicado: (2022)

Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer
por: Umekita, Yoshihisa, et al.
Publicado: (2011)

Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting
por: García-Teijido, Paula, et al.
Publicado: (2016)

HPV infection and triple-negative breast cancers: an Italian case-control study
por: Piana, Andrea Fausto, et al.
Publicado: (2014)

Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
por: Darbeheshti, Farzaneh, et al.
Publicado: (2018)

Targeting EGFR and Monitoring Tumorigenesis of Human Lung Cancer Cells In Vitro and In Vivo Using Nanodiamond-Conjugated Specific EGFR Antibody
por: Lin, Yu-Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0t0ns39l15j4058idqt30tlfb1